EHA 2022: MOMENTUM Demonstrates Promise of Investigational Momelotinib in Myelofibrosis
The JAK1, JAK2, and ACVR1 inhibitor improved symptoms as well as splenomegaly and anemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.